796-P: Perceived Potential Benefits and Barriers for Using a Bionic Invisible Pancreas

Abstract

A fully implantable automated insulin delivery system consisting of an intraperitoneal pump and an implantable CGM sensor (Bionic Invisible Pancreas - BIP) is under development. The occurrence of potential benefits or barriers to the use of the BIP was assessed in people with diabetes under different treatment regimens (MDI, CSII, CSII and CGM) . They were asked to provide a rating of 9 potential benefits and potential barriers of BIP on a five-point Likert scale ranging from 1 - strongly disagree - to 5 - strongly agree. Data from 38 people with type 1 diabetes were analysed (MDI: n=12; CSII: n=14; CSII and CGM: n=12) . In general, participants reported more expected benefits than barriers. The main benefits were increased flexibility and better glucose levels. The main expected barriers related to problems in transferring control to BIP and fears about side effects of implantation (e.g. inflammation) . The benefits and barriers were similar in all three groups (p=0.861 and p=0.669 for differences between groups, respectively) . 76.3% of participants reported that they would use BIP. Participants reported more positive than negative expectations related to the BIP device, regardless of previous insulin treatment. In addition to the fear of side effects during implantation, giving control to the BIP device was perceived as challenging. The present work was supported by H2020-FETPROACT Project FORGETDIABETS, n. 951933 Disclosure N.Hermanns: Advisory Panel; Abbott Diabetes, Research Support; Becton, Dickinson and Company, Roche Diagnostics, Speaker's Bureau; Berlin-Chemie AG, Novo Nordisk, Sanofi. K.Finke-groene: Speaker's Bureau; Berlin-Chemie AG. B.Kulzer: Advisory Panel; Bayer AG, Bayer AG, Becton, Dickinson and Company, Becton, Dickinson and Company, Berlin-Chemie AG, Berlin-Chemie AG, Dexcom, Inc., Dexcom, Inc., Insulet Corporation, Novo Nordisk, Roche Diabetes Care, Sanofi, Sanofi-Aventis Deutschland GmbH, Research Support; Novo Nordisk, Roche Diabetes Care. D.Ehrmann: Advisory Panel; Dexcom, Inc., Consultant; mySugr, Roche Diabetes Care, Speaker's Bureau; Berlin-Chemie AG, Dexcom, Inc. Funding The present work was supported by H2020-FETPROACT Project FORGETDIABETS, n. 951933